JPRN-C000000057已完成3 期
Phase III Randomized Adjuvant Study of Exemestane Versus Anastrozole Versus Tamoxifen in Hormone-Responsive Postmenopausal Breast Cancer Patients - Phase III Randomized Adjuvant Study in Hormone-Responsive Postmenopausal Breast Cancer Patients (N-SAS BC 04)
-SAS BC 04 executive committee0 个研究点目标入组 300 人开始时间: 2005年8月12日最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 60years-old 至 ot applicable（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •(1)invasive carcinoma of other organs (less than 5 years after the last treatment) (2)Past breast cancer (3)Past deep venous embolism (4)HRT(hormone replacement therapy) for symptoms of menopause within 4weeks before treatment (5)Metachronous or synchronous bilateral breast cancer (6)Patients judged inappropriate for this study by the physicians
研究者
相似试验
进行中（未招募）
不适用
Tamoxifen and Exemestane Trial (TEXT)Premenopausal women with histologically proven, resected breast cancer with ERand/or PgR positive tumorsMedDRA version: 14.0Level: PTClassification code 10057654Term: Breast cancer femaleSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2004-000168-28-SEInternational Breast Cancer Study Group (IBCSG)2,639
进行中（未招募）
1 期
A Phase III Trial Evaluating the Role of Exemestane Plus GnRH Analogue as Adjuvant Therapy for Premenopausal Women with Endocrine Responsive Breast Cancer - Tamoxifen and Exemestane Trial (TEXT)Premenopausal women with histologically proven, resected breast cancer with ERand/or PgR positive tumorsMedDRA version: 19.0Level: PTClassification code 10057654Term: Breast cancer femaleSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2004-000168-28-DEGBG Forschungs GmbH2,639
进行中（未招募）
不适用
Tamoxifen and Exemestane Trial (TEXT)EUCTR2004-000168-28-BEInternational Breast Cancer Study Group (IBCSG)2,639
进行中（未招募）
1 期
A randomized phase III trial of exemestane versus anastrozole in postmenopausal women with receptor positive primary breast cancer - MA.27Post-menopausal women, histologically or cytologically confirmed, receptor-positive,adequately excised, primary breast cancerEUCTR2005-001893-28-HUInternational Breast Cancer Study Group (IBCSG)7,576
进行中（未招募）
1 期
A randomized phase III trial of exemestane versus anastrozole in postmenopausal women with receptor positive primary breast cancer - MA.27EUCTR2005-001893-28-BEInternational Breast Cancer Study Group (IBCSG)5,800